National Research (NRC) Company Overview

LINCOLN, Neb.--(BUSINESS WIRE)-- #BIK--NRC Health, a leader in advanced technology and data-driven insights to deliver Human Understanding across the healthcare ecosystem, has proudly announced its recognition as the recipient of the esteemed 2025 Best in KLAS Award for Healthcare Experience Management for the second time in three years. This award once again underscores NRC Health's relentless pursuit of excellence in healthcare experience management through innovation and deep partnerships, in which.

LINCOLN, Neb.--(BUSINESS WIRE)--National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the fourth quarter 2024 and other corporate developments. Financial Results Revenue for the quarter was approximately $36.9 million compared with approximately $38.0 million in the 2023 quarter. Earnings per diluted share were $0.28 compared with $0.36 for the 2023 quarter. At December 31, 2024, the Company's net indebtedness (total borrowing minus cash and cash equivalents) w.

Funding: BTQ Technologies will receive funding of up to $150,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). This funding will enhance BTQ's IP portfolio, contributing to the company's R&D efforts.

Discover why Zacks has given NRC Health a "Neutral" rating, being the first on Wall Street to initiate coverage on the stock. Dive into the company's AI innovations, strategic partnerships, and financial resilience, along with the challenges of revenue declines, rising debt and stiff competition.

LINCOLN, Neb.--(BUSINESS WIRE)--National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the third quarter 2024 and other corporate developments. Financial Results Revenue for the quarter was approximately $35.8 million compared with approximately $37.9 million in the 2023 quarter. Earnings per diluted share were $0.24 compared with $0.32 for the 2023 quarter. At September 30, 2024, the Company's net indebtedness (total borrowing minus cash and cash equivalents) w.

LINCOLN, Neb.--(BUSINESS WIRE)--National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the second quarter 2024 and several other corporate developments. Financial Results Revenue for the quarter was approximately $35 million compared with approximately $36 million in the 2023 quarter. Earnings per diluted share were $0.26 compared with $0.29 for the 2023 quarter. At June 30, 2024, the Company's net indebtedness (total borrowing minus cash and cash equivalents) w.

Tiktinsky's nearly 40 years of experience at the U.S. Nuclear Regulatory Commission to greatly assist NANO Nuclear in navigating the complex U.S. nuclear licensing process

National Research Corporation (NASDAQ:NRC) will host an online web simulcast of its first quarter earnings conference call on May 8, 2024. The Company's 2024 first quarter results will be disclosed after the market closes on May 7, 2024. The live broadcast of the conference call will start at 11:00 a.m. Eastern Time on May 8, 2024, with a 30-day online replay option.

LINCOLN, Neb.--(BUSINESS WIRE)--National Research Corporation (NASDAQ:NRC) today announced that it will provide an online web simulcast of its 2023 fourth quarter and year-end earnings conference call on Wednesday, February 14, 2024. The Company's results for the 2023 fourth quarter will be released after the close of the market on Tuesday, February 13, 2024. The live broadcast of National Research Corporation's conference call will begin at 11:00 a.m. Eastern Time on February 14, 2024. A 30-da.